Search
Maryland Paid Clinical Trials
A listing of 2693 clinical trials in Maryland actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
193 - 204 of 2693
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Location
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Popular Cities
Maryland is currently home to 2693 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Baltimore, Bethesda, Rockville and Annapolis. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer
Recruiting
Background:
About 5% to 10% of differentiated thyroid cancers become resistant to standard treatment with radioactive iodine. In these cases, treatment options are limited and generally not effective. Researchers want to see if they can better detect thyroid tumors by using a compound called 68Gallium-DOTATATE. This compound may bind to a tumor and make it visible during a positron emission tomography/computed tomography (PET/CT) scan. This information might help guide future research and treat... Read More
Gender:
ALL
Ages:
Between 18 years and 98 years
Trial Updated:
06/14/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Metastic Thyroid Cancer
Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies
Recruiting
Background:
Cytoreductive surgery (CRS) removes tumors in the abdomen. HIPEC is heated chemotherapy that washes the abdomen. CRS and HIPEC may help people with peritoneal carcinomatosis. These are tumors that have spread to the lining of the abdomen from other cancers. Researchers think they can improve results of CRS and HIPEC by choosing the chemotherapy drugs used in HIPEC.
Objective:
To see if HIPEC after CRS can be improved, by testing different chemotherapy drugs, using a model called t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/14/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Peritoneal Carcinomatosis, Peritoneal Mesothelioma, Ovarian Cancer, Gastrointestinal Cancer, Appendiceal Cancer
NT-I7, a Long-Acting Recombinant IL-7 Molecule, as an Immune Reconstitution Strategy for Lymphopenia in Patients With Progressive Multifocal Leukoencephalopathy
Recruiting
Background:
Progressive multifocal leukoencephalopathy (PML) is a brain infection. It is caused by a virus. PML can happen in people with a weakened immune system. PML is associated with cognitive and visual impairment as well as motor and speech disturbances. There is no treatment for PML. Researchers want to see if a new drug can help.
Objective:
To see if the drug NT-I7 can help increase lymphocyte numbers, which may help control PML infection.
Eligibility:
Adults ages 18 and older with... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
06/14/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Progressive Multifocal Leukoencephalopathy
Safety, Tolerability, and Bioeffects of Alirocumab in Non-treatment Seeking Heavy Drinkers
Recruiting
Background:
Drinking alcohol can lead to swelling and injury in the liver. Long-term heavy drinking may lead to liver disease. Researchers want to study the relationship between a drug called alirocumab, alcohol use, and liver functioning/swelling.
Objective:
To study the effects of alirocumab in people who drink alcohol.
Eligibility:
Healthy adults ages 21 to 65 who regularly consume an average of 20 or more drinks per week.
Design:
Participants will be screened under protocol 14-AA-0181... Read More
Gender:
ALL
Ages:
Between 21 years and 65 years
Trial Updated:
06/14/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Alcohol Associated Liver Disease, Heavy Drinking Behavior
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel
Recruiting
Background:
People with rare cancers often have limited treatment options. The biology of rare cancers is not well understood. Researchers want to find better treatments for these cancers. They want to test 2 drugs that, taken separately, have helped people with non-rare cancers. They want to see if these drugs together can make rare cancers shrink or stop growing.
Objective:
To learn if nilotinib and paclitaxel will benefit people with rare cancers.
Eligibility:
People age 18 and older who... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
06/14/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Neoplasms
Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma
Recruiting
Background:
Thymoma and thymic carcinoma are diseases of the thymus. Platinum-based chemotherapy is the standard treatment for these diseases. But in many cases, the disease returns after treatment. Researchers want to see if a new drug can help.
Objective:
To see if bintrafusp alfa (M7824) is an effective treatment for thymoma and thymic carcinoma.
Eligibility:
People age 18 and older who have thymoma or thymic cancer and their disease returned or progressed after treatment with at least o... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/14/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Thymic Epithelial Tumor, Recurrent Thymoma, Thymic Cancer
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity
Recruiting
Background:
During a transplant, blood stem cells from one person are given to someone else. The cells grow into the different cells that make up the immune system. This can cure people with certain immunodeficiencies. But transplant has many risks and complications.
Objective:
To see if stem cell transplant can be successfully performed in people with primary immunodeficiency disease and cure them.
Eligibility:
People ages 4-69 for whom a primary immunodeficiency (PID) or Primary Immune Re... Read More
Gender:
ALL
Ages:
Between 4 years and 69 years
Trial Updated:
06/14/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Lymphoproliferative Disorders, Autoimmune Lymphoproliferative, Immune System Diseases, Common Variable Immunodeficiency, Primary T-cell Immunodeficiency Disorders
MK-7075 (Miransertib) in Proteus Syndrome
Recruiting
Background:
Proteus syndrome is a rare overgrowth disorder. Most people begin to have symptoms between 6 months and 2 years of age. There are very few living adults with this disease. There is also no known treatment for it. Researchers want to see if a new drug can slow down or stop overgrowth in people with Proteus syndrome.
Objective:
To learn if miransertib is a safe and effective treatment for Proteus syndrome.
Eligibility:
People ages 3 and older with Proteus syndrome.
Design:
Parti... Read More
Gender:
ALL
Ages:
Between 3 years and 99 years
Trial Updated:
06/14/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Proteus Syndrome
Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies
Recruiting
Background:
Genitourinary cancers are some of the most common types of cancer. They are lethal when they spread. The drug M7824 blocks the paths that cancer cells use to stop the immune system from fighting cancer. The drug PDS01ADC triggers the immune system to fight cancer. Researchers want to learn if these drugs can help fight these cancers when given with and without Stereotactic Body Radiation Therapy (SBRT) radiation.
Objective:
To learn if M7824 and PDS01ADC, with or without SBRT, can... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
06/14/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Urothelial Cancer, Bladder Cancer, Genitourinary Cancer, Urogenital Neoplasms, Urogenital Cancer
Optimizing PTCy Dose and Timing
Recruiting
Background:
Stem cell or bone marrow transplants can cure or control blood cancers. Sometimes the donor cells see the recipient's body as foreign. This can cause complications. A high dose of the drug cyclophosphamide (PTCy) can help reduce these risks. Researchers want to see if a lower dose of PTCy can have the same benefits. Based on encouraging results from the first part of the study, researchers now are investigating whether a lower dose of PTCy can allow other immunosuppression to be dec... Read More
Gender:
ALL
Ages:
Between 12 years and 120 years
Trial Updated:
06/14/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Graft Versus Host Disease, Hematologic Neoplasms
Collection of Bone Marrow Aspirate From Normal Volunteers
Recruiting
Background:
Bone marrow is the soft material found inside most large bones of the body. Bone marrow produces red blood cells, white blood cells, and platelets that are released into the blood stream. Inside the marrow, these cells start off as young, immature cells called progenitor cells. Researchers want to study these cells in healthy people.
Objective:
To understand how progenitor cells change with age.
Eligibility:
Healthy people ages 18 and older
Design:
Participants will be screene... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
06/14/2025
Locations: National Institute of Aging, Clinical Research Unit, Baltimore, Maryland
Conditions: Normal Aging
The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer
Recruiting
Study rationale
High risk patients with differentiated thyroid cancer (DTC) require therapy with 131 I under thyroid stimulating hormone (TSH) stimulation. There are two methods of TSH stimulation endogenous by thyroid hormone withdrawal (THW) leading to hypothyroidism and exogenous by injection of human recombinant TSH (rhTSH Thyrogen). The appropriate 131-I activity utilized for treatment is either based on empiric fixed dosage choice or individually determined activity based on 131 I dosimet... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
06/14/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Thyroid Cancer